A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Clinical trial NCT06345729 · RECRUITING
Trial details
- NCT number
- NCT06345729
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-05-24
- Primary completion
- 2029-02-19
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.